Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ksenia O. Shnaider
Observed names:
K. O. Schneider,
K. O. Shnaider,
K. Shnaider,
K.O. Shnaider,
Schneider K.O.,
Shnaider K.O.,
К. О. Shnaider
show all 7
Institutions:
Pirogov Russian National Research Medical University,
Ministry of Health of the Russian Federation
Observed institutions:
Pirogov Russian National Research Medical University,
Ministry of Health of the Russian Federation
ORCID:
0000-0002-0630-4238
Observed ORCID:
0000-0002-0630-4238
OpenAlex ID:
A5041244211
Safety of omalizumab in the treatment of moderate-to-severe bronchial asthma
2022
·
Ksenia O. Shnaider
, Maksim L. Maksimov
, et al.
·
Russian Medicine
·
8
PDF
Assessment of Practitioners' Awareness of Pharmacovigilance Procedures
2025
·
Shnaider K.O.
, Maksimov M.L.
·
Bulletin Biomedicine and sociology
·
2
Ways to increase freedom from DOAC-dependent complications in elderly patients with polypharmacy and chronic kidney disease: molecular and genetic aspects
2025
·
A. Kondrahin
, E. Silina
, et al.
·
Molekulyarnaya Meditsina (Molecular medicine)
·
1
Systematic Analysis of the Causes and Factors of Adverse Reactions of Omalizumab
2024
·
Schneider K.O.
, Maksimov M.L.
, et al.
·
Bulletin Biomedicine and sociology
·
1
Development and Validation of an Electronic Questionnaire to Assess the Professional Awareness of Doctors About the Procedure for Reporting Adverse Reactions to Drugs
2024
·
Schneider K.O.
, Maksimov M.L.
·
Bulletin Biomedicine and sociology
·
1
International Safety Profile for the Use of Omalizumab in Clinical Practice
2024
·
Schneider K.O.
, Maksimov M.L.
, et al.
·
Bulletin Biomedicine and sociology
·
1
PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
2023
·
K. O. Shnaider
, M. L. Maximov
, et al.
·
Safety and Risk of Pharmacotherapy
·
1
PDF
Efficacy and safety of antidepressant and antipsychotic combinations in the treatment of depression
2023
·
K. O. Shnaider
, M. L. Maksimov
, et al.
·
Glavvrač (Chief Medical Officer)
·
1
Efficacy and safety of modern second-generation antihistamines
2023
·
Ksenia O. Shnaider
, Maksim L. Maksimov
, et al.
·
Glavvrač (Chief Medical Officer)
·
1
The effect of lemon balm (Melissa officinalis L.) on anxiety and depression
2022
·
K. O. Shnaider
, M. L. Maksimov
, et al.
·
1
Participation of pharmaceutical workers in the pharmacovigilance system in the identification and registration of adverse drug reactions
2026
·
K. O. Shnaider
, V. A. Tkachuk
, et al.
Mechanism of action of various therapies for vitiligo. Pharmacologist’s and dermatovenerologist’s perspective
2025
·
V.V. Petunina
, M.L. Maksimov
, et al.
·
Russian Journal of Clinical Dermatology and Venereology
Safety study of omalizumab use during pregnancy
2025
·
K.O. Shnaider
, M.L. Maksimov
, et al.
·
Glavvrač (Chief Medical Officer)
Efficacy and safety of omalizumab use in chronic idiopathic urticari
2025
·
K.O. Shnaider
, A.P. Kondrakhin
, et al.
·
Glavvrač (Chief Medical Officer)
Safety analysis of tirzepatide in clinical practice
2025
·
K.O. Shnaider
, A.P. Kondrakhin
, et al.
·
Glavvrač (Chief Medical Officer)
Efficacy and safety of omalizumab for children and adolescents with atopic dermatitis (Literature review)
2025
·
K. O. Shnaider
, A. P. Kondrakhin
, et al.
·
Glavvrač (Chief Medical Officer)
Direct Oral Anticoagulants Prescription in the Elderly: Predictors of Adverse Outcomes
2025
·
A. Kondrakhin
, M. Maksimov
, et al.
·
Problems of Biological Medical and Pharmaceutical Chemistry
PDF
Efficacy and safety of benralizumab
2024
·
К. О. Shnaider
, M. L. Maksimov
, et al.
·
Glavvrač (Chief Medical Officer)
Global Safety of Benralizumab: Pharmacovigilance Analysis of Spontaneous Report Data
2024
·
Shnaider K.O.
, Maksimov M.L.
, et al.
·
Bulletin Biomedicine and sociology
Features of pharmacokinetics and safety of dabigatran, rivaroxaban and apixaban in elderly patients
2024
·
A.P. Kondrakhin
, K.O. Shnaider
, et al.
·
Glavvrač (Chief Medical Officer)
Comprehensive Analysis of the Causes of Adverse Reactions to Omalizumab
2024
·
Maksimov M.L.
, Schneider K.O.
, et al.
·
Bulletin Biomedicine and sociology
Safety of Omalizumab in Different Patient Populations
2024
·
Kondrakhin A.P.
, Maksimov M.L.
, et al.
·
Bulletin Biomedicine and sociology
Pharmacovigilance assessment of semaglutide safety
2024
·
K. O. Shnaider
, M. L. Maksimov
, et al.
·
Spravočnik vrača obŝej praktiki (Journal of Family Medicine)
Safety of dabigatran
2024
·
K. O. Schneider
, A. P. Kondrakhin
, et al.
·
Glavvrač (Chief Medical Officer)
Safety of rivaroxaban in elderly patients
2023
·
K. O. Shnaider
, A. P. Kondrakhin
, et al.
·
Glavvrač (Chief Medical Officer)
Show more works
View as search
Works count:
35
Citation count:
18
H-index:
2
I10-index:
Year
Topic
Type